NO814079L - ACID HALOGENIDES AND PROCEDURES FOR THEIR PREPARATION - Google Patents

ACID HALOGENIDES AND PROCEDURES FOR THEIR PREPARATION

Info

Publication number
NO814079L
NO814079L NO814079A NO814079A NO814079L NO 814079 L NO814079 L NO 814079L NO 814079 A NO814079 A NO 814079A NO 814079 A NO814079 A NO 814079A NO 814079 L NO814079 L NO 814079L
Authority
NO
Norway
Prior art keywords
acid
minutes
syn
water
approx
Prior art date
Application number
NO814079A
Other languages
Norwegian (no)
Inventor
Hans-Bodo Koenig
Karl Georg Metzger
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO814079L publication Critical patent/NO814079L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

I DE-OS 2 818 263 er ved siden av andre omtalt forbindelsen med formel I In DE-OS 2 818 263 the compound of formula I is mentioned alongside others

Den kan såvel eksistere i syn-form (imidazol idi - nonringen er rettet mot- cephem-strukturen), som også i anti-f or m. It can exist both in the syn-form (the imidazole idinon ring is directed towards the cephem structure), as well as in the anti-form.

Etter den i DE-OS 2 818 263 omtalte fremgangs-måter for fremstilling av disse forbindelser, blir imidlér-tid alltid den forhån sretningen med 7-aminocephalosporansyren anvendte syre, såvidt den har en aminogruppe, på forhånd ved aminogruppen utstyrt med en be skyttelsesgruppe, f. eks. According to the methods described in DE-OS 2 818 263 for the production of these compounds, however, the preferred acid used with the 7-aminocephalosporanic acid, as long as it has an amino group, is provided with a protective group in advance at the amino group, e.g.

Etter kobling av denne syren med 7-aminocephalosporansyren avspaltes deretter ved hjelp av trif1uoreddik-syre samtidig be skyttelsesgruppe, og under innvirkning av denne sterke syre, omdannes anti-formen delvis i syn-formen. Under innvirkning av trif1uoreddiksyre, innstiller det seg mellom syn- og nti-formen en likevekt, hvori begge former er inneholdende omtrent de like deler. At det dreier seg om- likevekt, ser man deri at også den rene anti-form i trifluoreddiksyre i løpet av få øyeblikk-gir den samme blanding. Dessuten fremkommer cephalosporinene ifølge DE-OS 28 18 263 alltid i 'amorf form. After coupling this acid with the 7-aminocephalosporanic acid, the protecting group is then removed with the help of trifluoroacetic acid, and under the influence of this strong acid, the anti-form is partially converted into the syn-form. Under the influence of trifluoroacetic acid, an equilibrium is established between the syn- and nti-forms, in which both forms contain approximately equal parts. That it is a question of equilibrium can be seen from the fact that even the pure anti-form in trifluoroacetic acid gives the same mixture within a few moments. Furthermore, the cephalosporins according to DE-OS 28 18 263 always appear in amorphous form.

Det er nå overraskende funnet at man direkte kan fremstille rene og under tiden krystallinske syn - cephalosporiner med den generelle formel III It has now surprisingly been found that pure and currently crystalline syn-cephalosporins of the general formula III can be directly prepared

i nærvær av en sterk.syre, f. eks. saltsyre, og i fravær av baser. in the presence of a strong acid, e.g. hydrochloric acid, and in the absence of bases.

Den rene syn-form har vist seg vesentlig mere virksom enn anti-formen. The pure syn-form has proven significantly more effective than the anti-form.

Oppfinnelsen vedrører, f ølgel.ig cephalosporinerThe invention relates, for example, to cephalosporins

i ren form med den generelle formel III, hvori n betyr 2, 3 eller i, in pure form of the general formula III, in which n means 2, 3 or i,

R betyr hydrogen, et farmasøytisk tålbart metall kation, fortrinnsvis natrium, et ammoniumkation av en farmasøytisk til-bar nitrogenbase, fortrinnsvis lysin, orn itin eller trieta-nolamin, eller resten av en ester, fortrinnsvis R means hydrogen, a pharmaceutically acceptable metal cation, preferably sodium, an ammonium cation of a pharmaceutically acceptable nitrogenous base, preferably lysine, ornithine or triethanolamine, or the residue of an ester, preferably

og T betyr: and T means:

- CHy -CH2-0-C0-CH3, -0-C0-NH2, med Z = 0 eller S - CHy -CH2-0-C0-CH3, -0-C0-NH2, with Z = 0 or S

Oppfinnelsen vedrører videre en fremgangsmåte til fremstilling av slike cephalosporiner, der fremgangsmåten erkarakterisert vedat et tilsvarende 7-aminocephalosporansyre-derivat omsettes med et syrehalogenid med formel IV The invention further relates to a method for producing such cephalosporins, where the method is characterized by reacting a corresponding 7-aminocephalosporanic acid derivative with an acid halide of formula IV

hvori in which

n har den ovenfor angitte betydning, ogn has the meaning stated above, and

X betyr en halogenrest, fortrinnsvis klor.X means a halogen residue, preferably chlorine.

Forbindelsene med den generelle formel III kan også foreligge som indre salter, idet R^ bortfaller og karboksylgruppen istedenfor denne har en negativ ladning, mens en annen gruppering i molekylet har en positiv ladning. The compounds with the general formula III can also exist as internal salts, with R^ omitted and the carboxyl group instead has a negative charge, while another grouping in the molecule has a positive charge.

Omsetningen gjennomføres fortrinnsvis i et inert oppløsningsmiddel, f. eks. tetrahydrofuran (THF). Derved arbeides det vanligvis ved en temperatur fra -80 til +25°C, The reaction is preferably carried out in an inert solvent, e.g. tetrahydrofuran (THF). Thereby, work is usually done at a temperature from -80 to +25°C,

og fortrinnsvis fra -50 til 0°C.and preferably from -50 to 0°C.

Fortrinnsvis silyleres cephalosporansyrederivater før omsetningen med syrehalogenidene med formel IV i aminogruppen, og karboksylgruppen f. eks. innføres trimetyl-silyl-, trietylsilyl eller andre silylrester. Cephalosporanic acid derivatives are preferably silylated before the reaction with the acid halides of formula IV in the amino group, and the carboxyl group e.g. trimethylsilyl, triethylsilyl or other silyl residues are introduced.

Reaksjonen gjennomføres videre i fravær av baser. Dette er spesielt nødvendig, fordi syrehalogenidene (IV) er basefølsomme. Under disse reaksjonsbetingelser må imidlertid det ansees som overraskende at de ønskede forbindelser fåes i dan rene syn-form, da som nevnt ovenfor, under innvirkning av sterk syre som trifluoreddiksyre, fåes av anti-forbindelsene en likevektsblanding av syn- og anti-forbindelse. The reaction is carried out further in the absence of bases. This is particularly necessary, because the acid halides (IV) are base-sensitive. Under these reaction conditions, however, it must be considered surprising that the desired compounds are obtained in pure syn form, since, as mentioned above, under the influence of a strong acid such as trifluoroacetic acid, an equilibrium mixture of syn and anti compounds is obtained from the anti-compounds.

De som utgangsprodukter anvendte syn-syrehalogenider (IV) er nye, og omfattes også av oppfinnelsen. Disse syrehalogenider kan fremstilles på følgemde måte: The zinc acid halides (IV) used as starting products are new, and are also covered by the invention. These acid halides can be prepared in the following way:

Ved omsetning av aminotiazolylglyoksylsyreIn the reaction of aminothiazolylglyoxylic acid

med hydrazinforbindelsen hvori n har overnevnte betydning, får man overraskende syn-syren med formel V with the hydrazine compound in which n has the above-mentioned meaning, one surprisingly obtains the syn-acid of formula V

nvon n nar overnevnteDetyanmg. nvon n nar above-mentionedDetyanmg.

At det derved dannes syn-formen er overraskende fordi ved omsetning av en tilsvarende aminotiaxolylglyoksyl-syre som bare ved aminogruppen har en be skyttelsesgruppe (BOC-rest) med en tilsvarende hydrazinforbindelse fåes anti- The fact that the syn form is thereby formed is surprising because by reacting a corresponding aminothiaxolylglyoxylic acid which only has a protecting group (BOC residue) at the amino group with a corresponding hydrazine compound, anti-

Syn- og anti-formen kan man adskille ved hjelp The syn- and anti-forms can be separated using

av NMR-spektrum. Eksempelvis -CI^-CHj-gruppen i imidazolyl-inondelen gir i syn-formen to multipletter, mens anti-formen viser en pseudosingulett. of NMR spectrum. For example, the -CI^-CHj group in the imidazolyl-inon part gives in the syn form two multiplets, while the anti form shows a pseudosinglet.

Syn-syren med formel V med n = 2, lar seg bare under bestemte betingelser overføre med tionylklorid i syn-syreklorid-hydroklorid med formel IV. Til disse betingelser behøver mam ikke fjerne de syrer med formel V inneholdte krystallvann, og til oppløsningsmiddelet dessuten setter så meget vann før tilsetningen av tiowylkloridet, at det i reaksjonsblandingen er inneholdt ca. 2- i molekvivalenter vann, referert til syn-syren (V). Syn-syrene med formel V med n = 3 eller 4, lar seg tørket med tionylklorid (0,4 molekvivalent H^O) eller utørket (1,7 molekvivalent H,,0) overføre i syn-syreklorid-hydrokloridet med formel (IV). The syn acid of formula V with n = 2 can only be transferred under certain conditions with thionyl chloride into syn acid chloride hydrochloride of formula IV. For these conditions, it is not necessary to remove the crystal water contained in the acids with formula V, and to the solvent, moreover, add so much water before the addition of the thioyl chloride, that the reaction mixture contains approx. 2- in molar equivalents of water, referred to the syn-acid (V). The syn acids of formula V with n = 3 or 4, dried with thionyl chloride (0.4 mol equivalent H^O) or dried (1.7 mol equivalent H,,0) can be transferred into the syn acid chloride hydrochloride of formula (IV ).

Som oppløsningsmiddel anvendes acetonitril eller en lavere nitroalifat, f. eks. nitrometan. Tionylkloridet må ved denne omsetning anvendes i stort overskudd. Mol-forholdet mellom syre (V) og tinonylklorid utgjør minst 1:3»fortrinnsvis 1:12. Man kan også anvende selve tionylklorid som fortynningsmiddel, det får imidlertid da syreklorid-hydrokloridet ikke i samme renhet. Acetonitrile or a lower nitroaliphate, e.g. nitromethane. The thionyl chloride must be used in large excess in this reaction. The molar ratio between acid (V) and tinonyl chloride is at least 1:3, preferably 1:12. One can also use thionyl chloride itself as a diluent, but the acid chloride hydrochloride is not obtained in the same purity.

Halogeneringen av syren V foregår vanligvis ved en temperatur fra 0 til 30°C, fortrinnsvis ved 15 til 25°C. The halogenation of the acid V usually takes place at a temperature of from 0 to 30°C, preferably at 15 to 25°C.

2-aminotiazol-rester kan også betegnes eller skrives som 2-imino-4-tiazolinrester. Fig. 1 viser IR-spektrum av forbindelser ifølge eks. 3b in nujol. Fig. 2 viser IR-spektrum av forbindelsen ifølge eksempel 4 in nujol. 2-Aminothiazole residues can also be designated or written as 2-imino-4-thiazoline residues. Fig. 1 shows the IR spectrum of compounds according to ex. 3b in nujol. Fig. 2 shows the IR spectrum of the compound according to example 4 in nujol.

Eksempel 1Example 1

2 - (2-imino-4-tiazolin-4-yl)-N-(imidazolidin -2 -on - 1-yl)-2-iminoeddiksyre (syn-form ). 2-(2-imino-4-thiazolin-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetic acid (syn form).

Til oppløsningen av 7, 6 g 1 -amino -2 -oxoimida,-zolidin i 90 ml vann, setter man 10 g 2-(2-imino-4-tiazolin - 4.-yl ) -glyoksylsyre og omrører ved 20°C natten over. Det utkrystalliserte produkt fras.uges, vaskes med vann og tørkes i exikator. To the solution of 7.6 g of 1-amino-2-oxoimida,-zolidin in 90 ml of water, 10 g of 2-(2-imino-4-thiazolin-4.-yl)-glyoxylic acid is added and stirred at 20°C overnight. The crystallized product is filtered off, washed with water and dried in a desiccator.

Utbytte: 7,2 g, sm.p.: >240°C.Yield: 7.2 g, m.p.: >240°C.

CgH9N503SxH20 CgH9N503SxH20

NMR (100 HHz 6 i dg-DHSO/CD^OD) 6,88 (s tiazolin-5-H) 3,9-3,7 (m N-CH2-CH2-N), 3,5-3,27 (m N-CHj-CHj-N). NMR (100 Hz 6 in dg-DHSO/CD^OD) 6.88 (s thiazoline-5-H) 3.9-3.7 (m N-CH2-CH2-N), 3.5-3.27 (m N-CHj-CHj-N).

Eksempel 2a Example 2a

2-(2-imino-4-tiazolin -4-yl )-N-(imidazolidin-2-on-~' 2-(2-imino-4-thiazolin-4-yl)-N-(imidazolidin-2-one-~'

1 -yl )-2-iminoeddiksyreklorid-hydrokloiid.1-yl)-2-iminoacetic acid chloride hydrochloride.

4-» 65 g 2-(2-imino-4-tiazolin-4-yl) -N-(imidazolidin - 2-on-1yl)-2-iminoeddiksyre syn-form med hensyn til karboksylgruppen (kornstørrelse til 98 % <£ 5u> stoffet inneholder 1,8 molekvivalenter vann) suspenderes i 96 ml acetonitril, (vanninnhold 0,30$), og tilsettes under tørr N216 ml tionylklorid ved 20°C..Man omrører i 1,5 timer ved 20°C, frasuger deretter den utfelte krystallinske gule utfelling under fuktighetsutelukkelse, og vasker to ganger med absolutt acetonitril. Etter tørkning i exikator utgjør utbyttet: 5,0 g (ca. 100 % 4-» 65 g of 2-(2-imino-4-thiazolin-4-yl)-N-(imidazolidin-2-on-1yl)-2-iminoacetic acid syn-form with respect to the carboxyl group (grain size to 98% <£ 5u> the substance contains 1.8 mole equivalents of water) is suspended in 96 ml of acetonitrile, (water content 0.30$), and added under dry N216 ml of thionyl chloride at 20°C.. One stirs for 1.5 hours at 20°C, suction then the precipitated crystalline yellow precipitate under moisture exclusion, washing twice with absolute acetonitrile. After drying in a desiccator, the yield is: 5.0 g (approx. 100%

av det teoretiske).of the theoretical).

IR-spektrum (nujol) (karbonylområde): 1810 (C0-C1), 1660-1668, 1625 (f ingeravtrykkområdet): 975, 890, 855, 800, IR spectrum (nujol) (carbonyl region): 1810 (C0-C1), 1660-1668, 1625 (fingerprint region): 975, 890, 855, 800,

775 oh 725 cm"<1.>775 oh 725 cm"<1.>

Stoffet er meget fuktighetsfølsomt. Ved absolutt utelukkelse av fuktighet og ved en temperatur på 0°C, var det også uendret etter flere uker. The fabric is very sensitive to moisture. With the absolute exclusion of moisture and at a temperature of 0°C, it was also unchanged after several weeks.

Eksempel 2bExample 2b

Blandingen av 5 g av den i eksempel 2 anvendte syre, 100 ml nitrometan (vanninnhold 0,17 %) og 50 ml nitrometan (vanninnhold 0,02 %) samt 5,7 ml tionylklorid ble omrørt under fuktighetsutelukkelse i 24 timer ved 20°C. Den dannede utfelling ble deretter frasuget, vasket med absolutt nitrometan, og tørket i exikator. The mixture of 5 g of the acid used in example 2, 100 ml of nitromethane (water content 0.17%) and 50 ml of nitromethane (water content 0.02%) as well as 5.7 ml of thionyl chloride was stirred under moisture exclusion for 24 hours at 20°C . The precipitate formed was then filtered off with suction, washed with absolute nitromethane, and dried in a desiccator.

Utbytte: 5,3 g.Yield: 5.3 g.

IR-spektrum: identisk med dette fra eksempel 2a. IR spectrum: identical to that from example 2a.

Eksempel 2cExample 2c

Anvender .man hver gang 0, 5 g av den i eksempel 2a anvendte syre som oppløsningsmiddel 1-nitropropan (15 ml) og 1,72 ml tionylklorid, så får man etter forsøksutførelsen som i eksempel 2b, syreklorid-hydroklorid i eksempel 2a i omtrent kvantitativt utbytte, når vanninnholdet av 1-nitropropan utgjør 0,19 %. Inneholder det anvendte 1-nitro- If each time 0.5 g of the acid used in example 2a is used as solvent 1-nitropropane (15 ml) and 1.72 ml thionyl chloride, then after carrying out the experiment as in example 2b, the acid chloride-hydrochloride in example 2a is obtained in approx. quantitative yield, when the water content of 1-nitropropane amounts to 0.19%. Contains the used 1-nitro-

propan bare 0,04 % vann, så oppstår praktisk talt intet syreklorid ■ (ifølge IR-spektrum). propane only 0.04% water, then practically no acid chloride occurs ■ (according to the IR spectrum).

Eksempel 2dExample 2d

Anvender man istedenfor 0,5 g av den i eksempelIf you use 0.5 g of it in the example instead

2a anvendte syre, som oppløsningsmiddel 15 ml nitrometan og 0,6 ml tionylklorid, så får man etter 24 timers omrøring ved 20°C syreklorid -hydroklor.id ifølge eksempel 2a i meget godt utbytte når vanninnholdet av nitrometan utgjør 0,17 %. Ved et vanninnhold av oppiøsningsmiddelet på 0,02 %, opp-■ trer reaksjonsproduktets IR-spektrum ingen bå° nd ved 1810 cm -1, d.v.s. det ble praktisk talt ikke dannet syreklorid. 2a used acid, as solvent 15 ml of nitromethane and 0.6 ml of thionyl chloride, then after 24 hours of stirring at 20°C acid chloride -hydrochloride according to example 2a is obtained in very good yield when the water content of nitromethane amounts to 0.17%. At a water content of the solvent of 0.02%, the IR spectrum of the reaction product shows no band at 1810 cm -1, i.e. practically no acid chloride was formed.

Eksempel 2eExample 2e

Omrører man blandingen av 10 g av den i eksempel 2a anvendte syre, 300 ml 2-nitropropan (vanninnhold 0,19 %) Stir the mixture of 10 g of the acid used in example 2a, 300 ml of 2-nitropropane (water content 0.19%)

og 34,4- ml tionylklorid i 24 timer ved 20°C, så får man syreklorid-hydroklor id fra eksempel 2a som utfelling og i omtrent kvantitaivt utbytte. and 34.4 ml of thionyl chloride for 24 hours at 20°C, the acid chloride hydrochloride id from example 2a is obtained as a precipitate and in approximately quantitative yield.

Senker man imidlertid ved dette forsøk bare mengden av 2-nitropropan til 150 ml (ved samme vanninnhold på 0,19 så viser-det utfelte reaksjonsprodukt i IR-spektrum intet syrekloridbånd ved 1810 cm~<1.>However, if in this experiment the amount of 2-nitropropane is reduced to 150 ml (at the same water content of 0.19, the precipitated reaction product shows no acid chloride band in the IR spectrum at 1810 cm~<1.>

Eksempel 3a 7 - /12 - am in otiazol-4 -yl) -N -(imidazol id in -2-on-1-y 1 ) - 2 -iminoacetamido7-3-acetoksymetyl -3-cephem-4-karbon surt natrium (syn-form) (amorf). Example 3a 7- /12-aminothiazol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetamido7-3-acetoxymethyl-3-cephem-4-carbonic acid sodium (syn-form) (amorphous).

Blandingen av 16,1 g 7-aminocephalosporansyre (94$-ig) og 110 ml tørr tetrahydrofuran blandes under omrøring ved 20°C med 32 ml bis-trimetylsilylacetamid. Den går i opp-løsning under svak temperaturøkning i løpet av ca. 2 minutter. Denne oppløsning avkjøles til -50°C, og tilsettes under N220,2 g av det i følge eksempel 2a fremstilte syreklorid-hydroklorid. Man omrører ennå 10 minutter i kuldebad idet temperaturen synker til -65°C. Deretter fjernes kuldebadet. Etter ca, 20 minutter er temperaturen øket til 0 - 5°C, og alt er gått i oppløsning. Nå heller man reaksjonsoppløsningen under omrøring i 3 liter eter og omrører i et åpent kar ca. 30 minutter. Den da dannede utfelling består av det amorfe hydro- The mixture of 16.1 g of 7-aminocephalosporanic acid (94 µg) and 110 ml of dry tetrahydrofuran is mixed with stirring at 20°C with 32 ml of bis-trimethylsilylacetamide. It dissolves under a slight increase in temperature during approx. 2 minutes. This solution is cooled to -50°C, and under N2 20.2 g of the acid chloride hydrochloride prepared according to example 2a is added. The mixture is stirred for a further 10 minutes in a cold bath as the temperature drops to -65°C. The cold bath is then removed. After approx. 20 minutes, the temperature has been increased to 0 - 5°C, and everything has dissolved. Now pour the reaction solution while stirring into 3 liters of ether and stir in an open vessel for approx. 30 minutes. The then formed precipitate consists of the amorphous hydro-

klorid av det i overskriften nevnte cephalosporin (syn-chloride of the cephalosporin mentioned in the title (syn-

form). Utfellingen suges fra, vaskes med eter og deretter innføres i løpet av 20 minutter porsjonsvis i 1,2 liter vann av 0 - 5°C under omrøring. Ved samtidig tilsetning av fast NaHCO^ eller natronlut holdes blandinges pH shape). The precipitate is suctioned off, washed with ether and then introduced in portions over 20 minutes into 1.2 liters of water at 0 - 5°C with stirring. By simultaneously adding solid NaHCO^ or caustic soda, the pH of the mixture is maintained

på ca. 3- Deretter innstilles pH på 3,2, omrøres ennå 15 -of approx. 3- Then the pH is set to 3.2, stirred for another 15 -

20 minutter og deretter frasuges, eventuelt gelaktig utfelling som i det vesentlige inneholder forurensninger. Derved holdes filtratet ved tilsvarende tilsetninger av 2n natronlut ved pH 5, og avkjøles. Den gelaktige utfelling vaskes grun.dig med isvann, (200 ml). De forenede vandige filtrater innstilles på pH 6,5 og frysetørkes. Man får så-ledes det amorfe natriumsalt av det i overskriften nevnte cephalosporin (syn-form). 20 minutes and then suctioned off, possibly gel-like precipitation which essentially contains contaminants. The filtrate is thereby kept at pH 5 by corresponding additions of 2N caustic soda, and cooled. The gel-like precipitate is washed thoroughly with ice water (200 ml). The combined aqueous filtrates are adjusted to pH 6.5 and freeze-dried. The amorphous sodium salt of the cephalosporin (syn form) mentioned in the title is thus obtained.

Utbyttet svinger ved flere blandinger mellomThe yield fluctuates with several mixtures between

24,2 og 32, 7 g. 24.2 and 32.7 g.

Innholdet av syn-form utgjør ifølge HPLC ca, 75 %• Anti-form er bare til stede til<<>1 %. Råproduktet inneholder NaCl (ca. 5 %) acetamid (ca. 1 molekvivalent) og vann (ca. 1 - 2 molekvivalenter). According to HPLC, the content of syn-form amounts to approx. 75%• Anti-form is only present to<<>1%. The raw product contains NaCl (approx. 5%), acetamide (approx. 1 molar equivalent) and water (approx. 1 - 2 molar equivalents).

NMR (100 MHz, 6 i CD30D-d6DMS0) 6,78, (s, tiazolin 5-H)., 5,75 (a,. 8-lactam, I = 4,7), 5,1 (a, S-lactam, I.= 4,7). NMR (100 MHz, 6 in CD30D-d6DMS0) 6.78, (s, thiazoline 5-H)., 5.75 (α,. 8-lactam, I = 4.7), 5.1 (α, S -lactam, I.= 4.7).

Eksempel 3bExample 3b

7- i (2-aminotiazol-4-yl)-N-(imidazolid in-2-on - 1 -yl ) -2 - iminoacetamino_/-3 -acetoksy metyl - 3-cephem-4-karbonsurt-natr ium. 7- i (2-Aminothiazol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetamino_/-3-acetoxy methyl-3-cephem-4-carbonic acid sodium.

(Syn-form) (krystallinsk) (etoanolat) (i vann lettoppløselig form). (Syn form) (crystalline) (ethanolate) (water soluble form).

62,6 g av et ifølge eksempel 3a fresmtillet62.6 g of a substance prepared according to example 3a

amorft syn-cephalosporin-natriumsalt oppløses i 250 ml vann ved 20°C. Til denne oppløsning setter man i første rekke under omsvinging 600 ml etanol, og etter at krystalliseringen er blitt satt i gang ved riving, ytterligere 400 ml etanol. amorphous syn-cephalosporin sodium salt is dissolved in 250 ml of water at 20°C. To this solution, 600 ml of ethanol are first added while swirling, and after the crystallization has been initiated by tearing, a further 400 ml of ethanol.

Man lar suspensjonen stå 5 minutter ved 20°C, frasuger, og vasker , med vandig etanol, (vann/alkohol = 1/4)^Utbytte 40,4 g« The suspension is allowed to stand for 5 minutes at 20°C, aspirated off, and washed with aqueous ethanol (water/alcohol = 1/4)^Yield 40.4 g«

Stoffet er krystallinsk, og -inneholder ifølge analyse og NMR-spektrum ca. 1 mol kry stallvann, og ca. 1 mol krystalletanol. The substance is crystalline, and - according to analysis and NMR spectrum, contains approx. 1 mol cry stable water, and approx. 1 mole of crystal ethanol.

NHR (<1>H-360 MHz i D20, 6 i ppm, I i Hz ) NHR (<1>H-360 MHz in D20, 6 in ppm, I in Hz )

3,210 og 3,5 (-A-CH2-, IAB ■= (-) 18,0) 3.210 and 3.5 (-A-CH2-, IAB ■= (-) 18.0)

5, 040 ( 6-lactam, I 4,7)5,040 (6-lactam, I 4.7)

5,710 ( 3-lactara, I = 4, 7)5.710 ( 3-lactara, I = 4, 7)

4,727 og 4, 560 . (-CH2-0-CO-, IAB= (-) 12,6) 1,910 (-0-C0-CH3) 4,727 and 4,560. (-CH2-0-CO-, IAB= (-) 12.6) 1.910 (-0-C0-CH3)

6, 810 (tiazol )6,810 (thiazole)

3,737 og 3,393 (-N-CH2-CH2-N-) 3.737 and 3.393 (-N-CH2-CH2-N-)

3,460 (CH2Et0H) 3.460 (CH2Et0H)

0, 982 (CH3EtOH)0.982 (CH3EtOH)

NMR (<13>C-25,2 MHz, 6 i ppm, i forhold til TMS = 0, i D20. NMR (<13>C-25.2 MHz, 6 in ppm, relative to TMS = 0, in D 2 O).

D-verdier og de dertil hørende intensiteter av en røntgenbøyeanalyse ifølge Debye-Scherrer (påvisning av kry stall initet): D values and the corresponding intensities of an X-ray diffraction analysis according to Debye-Scherrer (detection of crystallinity):

Eksempel 3c Example 3c

7 -/~(2 -aminotiazol -4-yl ) -N- (imidazol id in -2 -on -1 -yl - 2-iminoacetamido_/-3-acetoksymetyl -3-cephe m -4-kar bon surt - natrium (syn-form (krystallinsk). 7-/~(2-Aminothiazol-4-yl)-N-(imidazolidin-2-one-1-yl-2-iminoacetamido_/-3-acetoxymethyl-3-cephem-4-carbon acid - sodium (syn-form (crystalline).

67,3 g 7-aminocephalosporansyre (94 %- ig), 450 ml tørr tetrahydrofuran og 134 ml bis-trimetylsilylacetamid haes sammen i denne rekkefølge under tørr N2og omrøring. Etter at det er dannet en klar oppløsning ( iløpet av få minutter) avkjøles til -50°C, og tilsettes 84» 5 g av det i følge eksempel 2a fremstilte syreklorid-hydroklorid under omrøring. Man omrører deretter i ca. 10 minutter ved den samme temperatur, fjerner deretter kuldebadet, og lar temperaturen av seg selv stige til 0°C. Når da alt er gått i oppløsning, innhelles i 67.3 g of 7-aminocephalosporanic acid (94% strength), 450 ml of dry tetrahydrofuran and 134 ml of bis-trimethylsilylacetamide are combined in this order under dry N 2 and stirring. After a clear solution has formed (within a few minutes), it is cooled to -50°C, and 84" 5 g of the acid chloride-hydrochloride prepared according to example 2a are added while stirring. You then stir for approx. 10 minutes at the same temperature, then remove the cold bath and allow the temperature to rise to 0°C by itself. When everything has dissolved, pour in

blandingen av 4-000 ml tetrahydrofuran og 3 ml vann under om-røring, og den dannede utfelling frasuges. Denne utfelling innføres fuktig i 2000<*>) ml isvann under omrøring med ytterligere avkjøling med is, og derved holdes pH ved hjelp av 2n natronlut ved ca. 5- - 5,5, og innstilles til slutt på 6,5. ;Den dannede oppløsning inndampes deretter fra et bad på ca. 30-35°C til et volum på 800 til 1000 ml ved hjelp av en rotasjons-fordamper i vakuum, og blandes deretter under omrøring atter hvert med ca. 3000 ml etanol. Derved podes i mellomtiden med krystallinsk material. Deretter omrører man den dann-ede suspensjon ennå ca. 30 minutter,frasuger, vasker metanol/vann (4/1) og etanol, og tørkes i vakuum. ;Utbytte: 109.4 g (74$ av det teoretiske ref. til C18<H>18N7Na07S2x H20xC2H50H) (syn-form, krystallinsk). ;IR- og NMR-spektrum er identisk med stoffet som omtalt i eksempel 3b. Tørkning, eksempelvis i sirkulasjons-tørkeskap ved 40° - 70°C, kan man fjerne den i krystallene inneholdte etylalkohol. Stoffet beholder derfor den krystallinske tilstand, og syn-formen. IR-spekteret av det faste stoff endrer seg lite. ;<*>) Som alternativ kan man også oppløse i littthe mixture of 4-000 ml of tetrahydrofuran and 3 ml of water with stirring, and the formed precipitate is suctioned off. This precipitate is introduced moist into 2000<*>) ml of ice water while stirring with further cooling with ice, thereby maintaining the pH using 2N caustic soda at approx. 5- - 5.5, and is finally set to 6.5. The formed solution is then evaporated from a bath of approx. 30-35°C to a volume of 800 to 1000 ml by means of a rotary evaporator in vacuum, and then mixed with stirring each time with approx. 3000 ml of ethanol. Thereby inoculated in the meantime with crystalline material. The resulting suspension is then stirred for approx. 30 minutes, vacuum, wash methanol/water (4/1) and ethanol, and dry in vacuum. Yield: 109.4 g (74% of the theoretical ref. to C18<H>18N7Na07S2x H20xC2H50H) (syn form, crystalline). The IR and NMR spectrum is identical to the substance described in example 3b. Drying, for example in a circulation drying cabinet at 40° - 70°C, can remove the ethyl alcohol contained in the crystals. The substance therefore retains the crystalline state and syn-form. The IR spectrum of the solid changes little. ;<*>) As an alternative, you can also dissolve in a little

vann (ca. 1 000 ml) og- deretter tilsettes'.ca 3000 ml etanol. Også da får man cephalosporiner i tilsvarende renhet og utbytte. water (approx. 1,000 ml) and then add approx. 3,000 ml of ethanol. Even then, cephalosporins are obtained in similar purity and yield.

Eksempel 3dExample 3d

7r-./~(2 -aminotiazol-4-yl)-N-(imidazolidin-2-on-1-yl) -2 - iminoace tamido_7-3 -ace toksy metyl - 3-cephem-4 - kar bon surt - natrium (syn-form) (krystallinsk). 7r-./~(2 -aminothiazol-4-yl)-N-(imidazolidin-2-on-1-yl) -2 - iminoace tamido_7-3 -ace toxy methyl - 3-cephem-4 - carbonic acid - sodium (syn-form) (crystalline).

Blandingen av 6 g (0,022 mol) 7-aminocephalosporansyre, 60 ml acetonitril (skilt over mol-sikt) og 5,4 ml (0,26 mol) hexametyldisilåzan dyppes under omrøring i et til 100°C foroppvarmet oljebad, og derved føres en svak N2_ strøm over den hurtig under tilbakeløp kokende suspensjon. The mixture of 6 g (0.022 mol) 7-aminocephalosporanic acid, 60 ml acetonitrile (separated over a mole sieve) and 5.4 ml (0.26 mol) hexamethyldisilazane is dipped with stirring into an oil bath preheated to 100°C, and thereby a weak N2_ stream over the rapidly refluxing boiling suspension.

Etter ca. 15 minutter har det dannet seg en klar oppløsning,After approx. 15 minutes a clear solution has formed,

og etter tilsammen ca. 1 time er det i damprommet over reaksjons- and after a total of approx. 1 hour it is in the steam room above the reaction

blandingen med indikatorpapir ikke mere påvisbart ammoniakk. Nå avkjøles ved 30°C, og under omrøring inndampes ved hjelp av en oljepumpe under forpumping av en kjølefelle (fl. Ng) reaksjonsoppløsningen inntil et volum på ca. 30 ml i det reaksjonskolben for å komplettere varmetapet, dyppes i et vannbad av værel sestemperatur. Den gjenblivende reaksjons-oppløsningen avkjøles deretter i is/vann til 5°C. 5,88 g the mixture with indicator paper no longer detectable ammonia. Now cool at 30°C, and with stirring the reaction solution is evaporated using an oil pump while pre-pumping a cooling trap (fl. Ng) until a volume of approx. 30 ml in the reaction flask to complete the heat loss, is dipped in a water bath of room temperature. The remaining reaction solution is then cooled in ice/water to 5°C. 5.88g

(0,019 Mol) av syrekloridhydrokloridet:(0.019 Mol) of the acid chloride hydrochloride:

tilsettes deretter på en gang. Den indre temperatur øker derved til 26°C. Når den indre temperatur igjen har sunket til 20"C, fj ernes isbadet og videreomrøres enna i 3 timer og 4-0 is then added all at once. The internal temperature thereby increases to 26°C. When the internal temperature has again dropped to 20°C, the ice bath is removed and further stirred for another 3 hours and 4-0

min. ved værelse stemperatur. Deretter innhelles reaksjonsblandingen i 600 ml eter ..(Ferak, HgO < 0, 1$), som omrøres i et åpent kar, etteromrøres 30 minutter, den dannede utfelling frasuges gjennom glassfrittet, vaskes en gang med eter på Nutchen, avpresses, og innføres fra nutchen i 60 ml isvann idet man samtidig ved tilsvarende tilsetning av 2n natronlut holder pH mellom 5 og 6. Deretter omrører man ennå i 10 minutter ved pH 7,5, og oppdeler derved klumpene av filterkaken. Man frafiltrerer en 1iten mengde uoppløst (forurensning), innstiller det klare filtrat (hvis nødvendig) igjen til pH 7,5 (volum nå ca. 120 ml) og tilsetter deretter 150 ml EtOH, tilsetter ytterligere 150 ml EtOH, omrører ved værelsestemperatur ca. 30 min, og frasuger deretter det krystallinske natriumsalt. Man vasker på nutchen 2 x med 20 ml EtOH/H20=5/l, og deretter 1 x med 2 0 ml EtOH. my. at room temperature. The reaction mixture is then poured into 600 ml of ether ..(Ferak, HgO < 0.1$), which is stirred in an open vessel, stirred for 30 minutes, the precipitate formed is suctioned off through the glass frit, washed once with ether on the Nutchen, pressed off, and introduced from the nut in 60 ml of ice water, while at the same time keeping the pH between 5 and 6 by the corresponding addition of 2N caustic soda. Then you stir for a further 10 minutes at pH 7.5, thereby breaking up the clumps of the filter cake. A large amount of undissolved (impurity) is filtered off, the clear filtrate (if necessary) is again adjusted to pH 7.5 (volume now approx. 120 ml) and then 150 ml EtOH is added, another 150 ml EtOH is added, stirring at room temperature approx. 30 min, and then aspirate off the crystalline sodium salt. The nut is washed twice with 20 ml EtOH/H20=5/l, and then once with 20 ml EtOH.

Utbytte (etter tørkning i exikator over PgO^^ 4, 7 g (45$ av det teoretiske) (krystallinsk). Yield (after drying in a desiccator over PgO^^ 4.7 g (45$ of the theoretical) (crystalline).

Rensning av det krystallinske råprodukt.Purification of the crystalline crude product.

4., 5 g av råproduktet oppløses i 45 ml vann ved værelse stemperatur under omrøring (går hurtig) og haes til en klar oppløsning med en gang '120 ml EtOH. Derved utskiller det seg få brune fnokker. Disse fjernes ved filtrering. Man ettervasker med noe EtOH. I filtratet setter man deretter under omrøring ytterligere 280 ml EtOH, river, og etterom- 4. Dissolve 5 g of the crude product in 45 ml of water at room temperature with stirring (proceeds quickly) and add 120 ml of EtOH to a clear solution at once. As a result, a few brown flakes are released. These are removed by filtration. Wash with some EtOH. A further 280 ml EtOH is then added to the filtrate while stirring, grated, and after

rører ved værel se stemperatur ennå i 5 minutter, Deretter frasuger man, vasker 2 x med 10 ml Et0G/H20=5/1 og 1 x med EtOH. stir at room temperature for another 5 minutes, then suction off, wash 2 x with 10 ml Et0G/H20=5/1 and 1 x with EtOH.

Utbytte: (exikator,. PgO^): 3. 2 g (krystallinsk) Yield: (desiccator,. PgO^): 3.2 g (crystalline)

(tilsvarer 32$ av det teoretiske).(equivalent to 32$ of the theoretical).

NMR (250 MHz, 6 i CD-^OD/DgO) 6in77 (tiazolin-5-H), 5,77(d, 1H, B-lactam), 5,07 (d, 1H, 3-lactam), 3.85 - 3.22 NMR (250 MHz, 6 in CD-^OD/DgO) 6 in 77 (thiazoline-5-H), 5.77(d, 1H, B-lactam), 5.07 (d, 1H, 3-lactam), 3.85 - 3.22

(m, 6H, C-2, imidazolidinon).(m, 6H, C-2, imidazolidinone).

Eksempel 4Example 4

7-/(2-aminoriozol-4-yl)-N-(imidazolidin-2-on-1-yl)-2 - iminoace tamidq_7-3-acetoksy me tyl -3 - cephe m-4-kar bon surt - . natrium(syn-form) (krystallinsk) (i vann tungtoppløselig form). 7-(2-aminoriozol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetamido_7-3-acetoxy methyl -3-cephe m-4-carbon acid - . sodium (syn form) (crystalline) (in water sparingly soluble form).

20 g av det under eksempel 3b omtalte i vann lett oppløselige krystallinske og etanolholdig natriumsalt opp- 20 g of the water-soluble crystalline and ethanol-containing sodium salt mentioned under example 3b

løses under omrøring i 100 ml vann av 20°C, og denne oppløsning videreomrøres etter podning ved den i vann tungt oppløselige form i 30 minutter. Derved har det utskilt seg den i vann tungt oppløselag krystallinske form. Utfellingen suges fra og tørkes i exikator over P^O^q. Stoffet inneholder etanol, is dissolved with stirring in 100 ml of water at 20°C, and this solution is further stirred after inoculation with the poorly water-soluble form for 30 minutes. Thereby, the crystalline form that is heavily soluble in water has separated. The precipitate is sucked off and dried in a desiccator over P^O^q. The substance contains ethanol,

men ca. 2 Molekvivalent vann.but approx. 2 Molar equivalent of water.

Utbytte: 11,65 gYield: 11.65 g

NMR (250 MHz, 6 i d6~DMS0) 9,82 (d, J 7, 5 Hz,NMR (250 MHz, 6 in d6~DMSO) 9.82 (d, J 7.5 Hz,

C-CO-NH), 7,5 (s N-CO-NH), 7,5 (d, HgN-tiazol), 6,73 (s, tiazol-5-H), 5,7 (dd, J 5Hz og 7,5 Hz, C?-H), 5,03 (d, 5 Hz, C-CO-NH), 7.5 (s N-CO-NH), 7.5 (d, HgN-thiazole), 6.73 (s, thiazole-5-H), 5.7 (dd, J 5Hz and 7.5 Hz, C?-H), 5.03 (d, 5 Hz,

C6-H), 5,01 og 4,79 (AB, J 12,5 Hz, CHg-O-CO), 3,9-3,2 (m,C6-H), 5.01 and 4.79 (AB, J 12.5 Hz, CHg-O-CO), 3.9-3.2 (m,

S-CH2, N-CH2-CH2-N, HgO), 2,02 (s, -CO-CHg).S-CH2, N-CH2-CH2-N, HgO), 2.02 (s, -CO-CHg).

D-verdier og de dertil hørende intensiteter av en røntgenbøyanalyse ifølge De bye-Scherrer (påvisning av krystallini- D values and the corresponding intensities of an X-ray diffraction analysis according to De bye-Scherrer (detection of crystallinity

tet): tight):

Eksempel 5 7 - £{ 2 -amiriotiazol -4 -yl ) -N - (imidazol idin -2 -on -1 -yl ) - 2-iminoacetamido/-3-acetoksymetyl-3-cephe m-4-karbon surt - L-lysin (syn-form). Example 5 7-£{2-amiriothiazol-4-yl)-N-(imidazolidin-2-one-1-yl)-2-iminoacetamido/-3-acetoxymethyl-3-cephe m-4-carbonic acid - L -lysine (syn form).

Blandingen av 100 g "Lewatit S 100" (H+<->form) The mixture of 100 g "Lewatit S 100" (H+<->form)

(sterk, sur ioneutveksier) og 500 ml vann avkjøles til 0°C. Under omrøring tilsettes deretter på en gang 10 g stoff, frem-stilt tilsvarende eksempel 3b (0,017 Mol) og videreomrøres ved samme temperatur. Etter 6 minutter er pH sunket fra til å begynne med 4,85 til 3.39. loneutveksieren filtreres deretter med en gang over et G-4 filter, og det klare filtrat innstilles med 2,15 g L-lysin (sigma) (0,015 Mol) i løpet av 20 minutter på pH 6,55. Denne oppløsningen ble deretter underkastet frysetørking. (strong, acidic ion exchanger) and 500 ml of water are cooled to 0°C. While stirring, 10 g of substance, prepared corresponding to example 3b (0.017 mol), is then added at once and further stirred at the same temperature. After 6 minutes the pH has dropped from the initial 4.85 to 3.39. the ion exchange is then filtered at once over a G-4 filter, and the clear filtrate is adjusted with 2.15 g of L-lysine (sigma) (0.015 Mol) during 20 minutes at pH 6.55. This solution was then subjected to freeze drying.

Utbytte: 9,6 g (87 % av det teoretiske) (amorf). Yield: 9.6 g (87% of theory) (amorphous).

NMR (250 MHz, 6 i CD^OD + D.,0) 6,96 (s, tiazolin-5-H), 5,91 (d, 1H, 3-lactam), 5,23 (d, 1H, B-lactara): 5,0 - 4,77 (AB, 2H, -CHg-O-CO-,. blant utve ksle bare ), 4,1 - 3,38 (m, 7H, C-2, imidazolidinon, lysin- a-H), 3,0 (t, 2H, lysin H2N-CH2-), 2,1 (s, 3H, -OCO-CH^), 1,96 - 1,45 (m, 6H. lysin ). NMR (250 MHz, 6 in CD^OD + D.,0) 6.96 (s, thiazoline-5-H), 5.91 (d, 1H, 3-lactam), 5.23 (d, 1H, B-lactara): 5.0 - 4.77 (AB, 2H, -CHg-O-CO-,. among exchange only ), 4.1 - 3.38 (m, 7H, C-2, imidazolidinone, lysine-α-H), 3.0 (t, 2H, lysine H2N-CH2-), 2.1 (s, 3H, -OCO-CH^), 1.96 - 1.45 (m, 6H. lysine ).

Eksempel 6Example 6

7-/(2-aminotiazol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetam idc_7-3-acetoksy metyl-3-cephem-4-karbon surt-L-lysin (syn-form). 7-(2-aminothiazol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetam idc_7-3-acetoxy methyl-3-cephem-4-carbon acid-L-lysine ( sight form).

Den til 0° - 5°C avkjølte blanding av 10 g "Lewatit S 100" (H<+>-form) og 30 ml vann (pH 3,4) blandes med 1 g stoff av eksempel 3b (0,0017 Mol) under omrøring, omrøres 10 minutter (pH deretter 3,4 konstant) og deretter frasuges ioneutveksleren. Filtratet innstilles med L-lysin (sigma) til pH 6,7, og deretter innhelles oppløsningen av 200 ml isopropanol under omrøring: Det faller ut en pulverformet utfelling som frasuges etter 3 minutter. Deretter ble utfellingen på fritten til slutt klebrig. Etter utrivning med frisk isopropanol kunne det tørrsuges. Utbytte 0,6 (50 % av det teoretiske) The cooled to 0° - 5°C mixture of 10 g of "Lewatit S 100" (H<+>-form) and 30 ml of water (pH 3.4) is mixed with 1 g of substance from example 3b (0.0017 Mol) while stirring, stir for 10 minutes (pH then 3.4 constant) and then suction off the ion exchanger. The filtrate is adjusted with L-lysine (Sigma) to pH 6.7, and then the solution of 200 ml of isopropanol is poured in while stirring: A powdery precipitate falls out which is sucked off after 3 minutes. Then the precipitate on the frit eventually became sticky. After stripping with fresh isopropanol, it could be vacuumed dry. Yield 0.6 (50% of theoretical)

(amorf).(amorphous).

NMR: identisk med dette fra eksempel 5.NMR: identical to this from Example 5.

Eksempel 7Example 7

Tilsvarende eksempel 5, ble det av hver gang 1 g stoff fra eksempel 3c med følgende base dannet de tilsvarende salter: Corresponding to example 5, each time 1 g of substance from example 3c with the following base formed the corresponding salts:

Eksempel 8 Example 8

1-[{ 2-aminotiazol-4 -yl)-N- (imidazolidin-2-on - 1 -yl )-2-iminoacetamido_7-3-acetoksymetyl -3-cephem-4^karbon - surt -natrium-1-oksyd (syn-form). 1-[{2-Aminothiazol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetamido_7-3-acetoxymethyl-3-cephem-4-carbon-acid-sodium-1-oxide (syn-form).

2,88 g 7-aminocephalosporansyre -S-oksyd silyleres som .i eksempel 3c i tetrahydrofuran ved hjelp av bis-trimetylsilylacetamid, omsettes med det ifølge eksempel 2a fremstilte syreklorid-hydroklorid. Reaksjonsblandingen helles deretter i meget absolutt eter, den dannede utfelling frasuges, oppløses i vann under tilsetning av natronlut ved pH 6,5»og denne oppløsninge frysetørkes. 2.88 g of 7-aminocephalosporanic acid -S-oxide is silylated as in example 3c in tetrahydrofuran using bis-trimethylsilylacetamide, reacted with the acid chloride hydrochloride prepared according to example 2a. The reaction mixture is then poured into very absolute ether, the precipitate formed is suctioned off, dissolved in water with the addition of caustic soda at pH 6.5 and this solution is freeze-dried.

Utbytte: 2, 0 gYield: 2.0 g

NMR (250 MHz, 6 i CD^D/DgO): 6,98 (s, 1H, tiazolin-5), 6,4 (d, 1H, J - 5HZ, 8-lactam), 5,1 u. 4.7 (AB, 2H, NMR (250 MHz, 6 in CD^D/DgO): 6.98 (s, 1H, thiazolin-5), 6.4 (d, 1H, J - 5HZ, 8-lactam), 5.1 u. 4.7 (AB, 2H,

-CH20Ac, J = 13,5 Hz), 4.94 (d, 1H, J = 5Hz, Ø-lactam),-CH20Ac, J = 13.5 Hz), 4.94 (d, 1H, J = 5Hz, Ø-lactam),

4,0 - 3.8 (ra, 3H,' CH2NH.u. 2-CH), 3» 6 - 3,46 (m, 3H, N-N-CH2u. 2-XH), 2,1 (s, 3H, C0-CH3). 4.0 - 3.8 (ra, 3H,' CH2NH.u. 2-CH), 3» 6 - 3.46 (m, 3H, N-N-CH2u. 2-XH), 2.1 (s, 3H, C0 -CH3).

Man kan også fremstille dette stoff fra stoffet ifølge eksempel 3a-d ved direkte oksydasjon ,med m-klorperbenzosyre i vann. This substance can also be produced from the substance according to example 3a-d by direct oxidation with m-chloroperbenzoic acid in water.

Aminocephalosporansyre-S-oksyd ble fremstillet ved fenyl-acetylaminocephalosporansyre-S-oksyd ved enzymatisk av spaltning av fenylacetylresten. Aminocephalosporanic acid S-oxide was prepared from phenyl-acetylaminocephalosporanic acid S-oxide by enzymatic cleavage of the phenylacetyl residue.

Eksempel 9 1 - [{ 2 -aminotiazol -4-yl )-N-(imidazolidin-2-on-1-yl)-2 - iminoacetamido_7-3-metyl - 3-cephem-4-kar bon surt -natrium (syn-form ). 5 g 7 aminodesacetoksycephalosporansyre silyleres som i eksempel 3d ved hjelp av hexametyldisilazan i aceton-nitril, omsettes deretter med ifølge eksempel 2a fremstillet syreklorid-hydroklorid. Reaksjonsblandingen omrøres til slutt ennå 4 timer ved 20°C, og helles deretter i 600 ml eter. Det omrøres 20 minutter, den dannede utfelling frasuges, og oppløses i isvann (60 ml) under tilsetning av 2N natronlut ved pH 6,5- Oppløsningen klarfiltreres fra små mengder forurensninger, og blandes deretter etter hvert med til sammen 600 ml EtOH. Den gel-aktige utfelling som danner seg, frasuges, vaskes godt med EtOH, og tørkes. Example 9 1-[{2-Aminothiazol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetamido_7-3-methyl-3-cephem-4-carboxylic acid sodium (syn -form ). 5 g of 7 aminodesacetoxycephalosporanic acid is silylated as in example 3d using hexamethyldisilazane in acetonitrile, then reacted with the acid chloride hydrochloride prepared according to example 2a. The reaction mixture is finally stirred for a further 4 hours at 20°C, and then poured into 600 ml of ether. It is stirred for 20 minutes, the formed precipitate is suctioned off, and dissolved in ice water (60 ml) with the addition of 2N caustic soda at pH 6.5. The solution is clearly filtered from small amounts of impurities, and then gradually mixed with a total of 600 ml of EtOH. The gel-like precipitate that forms is filtered off with suction, washed well with EtOH, and dried.

Utbytte: 2,15 gYield: 2.15 g

NMR MHz, 6, i CD^OD/DgO): 6,86 (s, 1H, tiazolin-5), 5,72 (d, 1H, J = 5HZ, B-lactam),. 5, 06 (d, 1H, J = 5Hz, B-lactam), 3.87 (t, 2H, N-N-CHg), 1,87 (s, 3H, 3-CH^). NMR MHz, 6, in CD₂OD/D₂O): 6.86 (s, 1H, thiazoline-5), 5.72 (d, 1H, J = 5HZ, β-lactam), . 5.06 (d, 1H, J = 5Hz, B-lactam), 3.87 (t, 2H, N-N-CH 2 ), 1.87 (s, 3H, 3-CH 2 ).

Eksempel 10 Example 10

7- 1( 2-aminotiazol-4-yl)-N- (imidazolid in-2-on-1 -yl) - 2 -iminoacetamido_/-3-metyl -3-cephe ra- 4 -kar bon surt -natrium -1 - oksyd (syn-form). 7- 1(2-aminothiazol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetamido_/-3-methyl-3-cephera-4-carbon acid -sodium - 1 - oxide (syn form).

2,14 g 7-aminodesacetoksycephalosporansyre-S-oksyd silyleres som i eksempel- 3c ved hjelp av bis-trimetylsilylacetamid i tetrahydrofuran, og omsettes deretter med syreklorid-hydroklorid ifølge eksempel 2a. Reaksjonsblandingen helles i meget eter, den dannede utfelling oppløses i isvann av pH 6,5»og oppløsningen frysetørkes. 2.14 g of 7-aminodesacetoxycephalosporanic acid S-oxide is silylated as in example 3c with the aid of bis-trimethylsilylacetamide in tetrahydrofuran, and is then reacted with acid chloride-hydrochloride according to example 2a. The reaction mixture is poured into a lot of ether, the precipitate formed is dissolved in ice water of pH 6.5 and the solution is freeze-dried.

Utbytte: 1,0 gYield: 1.0 g

NMR (250 MHz , <5, i CD30D(D20): 7,0 (s, 1H, tiazolin-5-), 6,0 (d, 1H,' B-lactam, J = 5Hz), 4.92 (d, 1H, B-lactam, J = 5Hz), 4.0-3,5 (m, N-CHg-CHg-N. u. 2-H), 1,97 NMR (250 MHz , <5, in CD30D(D20): 7.0 (s, 1H, thiazolin-5-), 6.0 (d, 1H,' B-lactam, J = 5Hz), 4.92 (d, 1H, B-lactam, J = 5Hz), 4.0-3.5 (m, N-CHg-CHg-N. u. 2-H), 1.97

(s, 3H, 3-CH3).(s, 3H, 3-CH3).

Man kan også fremstille dette stoff fra stoffet i eksempel 9 ved direkte oksydasjon med klorperbenzosyre i vann. This substance can also be prepared from the substance in example 9 by direct oxidation with chloroperbenzoic acid in water.

Aminodesacetoksycephalosporansyre-S-oksyd ble fremstillet av fenylacetylaminodesacetyloksycephalosporansyre-S-oksyd ved enzymatisk avspaltning av fenylacetylresten. Aminodeacetoxycephalosporanic acid S-oxide was prepared from phenylacetylaminodesacetyloxycephalosporanic acid S-oxide by enzymatic cleavage of the phenylacetyl residue.

Eksempel 11 Example 11

7-/~(2 -aminotiazol -4 -yl) -N- (imidazol id in -2 -on -1 -yl ) -2 -imino - acetamido_7'-3-aminokarbonyloksymetyl - 3-cephem-4-karboPsurt-natrium (syn-form) (krystallinsk). 7-[(2-aminothiazol-4-yl)-N-(imidazolidin-2-one-1-yl)-2-imino-acetamido_7'-3-aminocarbonyloxymethyl-3-cephem-4-carboPsourt-sodium (syn-form) (crystalline).

Blandingen av 1,68 g 7-amino-3-aminokarbonyloksy-metyl-3-cephem-4-karbonsurt natrium, 20 ml tetrahydrofuran The mixture of 1.68 g of 7-amino-3-aminocarbonyloxy-methyl-3-cephem-4-carboxylic acid sodium, 20 ml of tetrahydrofuran

og 0,4.2 ml triflubreddiksyre omrøres i 20 minutter ved 20°C. Deretter tilsettes 20 ml acetonitril, og deretter 6,2 ml bis-trimetylsilylacetamid, og omrøres i ytterligere 50 minutter. Blandingen avkjøles deretter til -50°C, 1,77 g av syreklorid-hydroklorid fra eksempel 2a tilsettes og omrøres deretter 10 minutter ved -50°C. Etter fjerning av kuldebadet, øker temperaturen i løpet av 30 minutter til + 10°C. Reaksjonsblandingen helles deretter i 200 ml eter, og omrøres i 10 minutter. Den dannede utfelling frasuges deretter, og vaskes med eter, og oppløses i 20 ml isvann under tilsetning av 1n natronlut ved pH 6, 7. Man fraf iltrerer mindre mengder forurensning, og blander filtratet (40 ml) etter hvert med til sammen 200 ml EtOH. Derved faller det ut natriumsalt som krystallinsk utfelling. and 0.4.2 ml of trifluacetic acid are stirred for 20 minutes at 20°C. 20 ml of acetonitrile are then added, and then 6.2 ml of bis-trimethylsilylacetamide, and stirred for a further 50 minutes. The mixture is then cooled to -50°C, 1.77 g of acid chloride-hydrochloride from example 2a is added and then stirred for 10 minutes at -50°C. After removing the cold bath, the temperature increases within 30 minutes to + 10°C. The reaction mixture is then poured into 200 ml of ether and stirred for 10 minutes. The formed precipitate is then suctioned off, and washed with ether, and dissolved in 20 ml of ice water with the addition of 1N caustic soda at pH 6.7. Small amounts of contamination are filtered off, and the filtrate (40 ml) is gradually mixed with a total of 200 ml of EtOH . As a result, sodium salt falls out as a crystalline precipitate.

Utbytte: 1,8 g.Yield: 1.8 g.

NMR (250 MHz, 6, i CD^OD/DgO): 6,85 (s, 1H, tiazolin-5), 5,8 (d, 1H, B-lactam, J = 5Hz), 5,1 (d, 1H, B-lactam, NMR (250 MHz, 6, in CD^OD/DgO): 6.85 (s, 1H, thiazoline-5), 5.8 (d, 1H, B-lactam, J = 5Hz), 5.1 (d , 1H, β-lactam,

J = 5Hz), 4,82-4,59 (AB, CHgOCONHg blan t utveksl bare ) 3, 86J = 5Hz), 4.82-4.59 (AB, CHgOCONHg between exchanges only) 3.86

(t, 2H, =N-N-CH2, J 8Hz), 3,59-3,24 (m, 4H, CHg-NH u. C-2). (t, 2H, =N-N-CH2, J 8Hz), 3.59-3.24 (m, 4H, CHg-NH u. C-2).

7-amino-3-aminokarbonyloksyme tyl-3-cephem-4-kar-boksyl syre -natrium ble fremstillet av 7-fenylacetylamino-3-amino-karbonyloksymetyl-3-cephem-4-karbonsurt natrium med enzymatisk avspaltning av fenylacetylresten. 7-Amino-3-aminocarbonyloxymethyl-3-cephem-4-carboxylic acid sodium was prepared from 7-phenylacetylamino-3-amino-carbonyloxymethyl-3-cephem-4-carboxylic acid sodium with enzymatic cleavage of the phenylacetyl residue.

Eksempel 12Example 12

7 -[(2 -aminotiazol -4-yl) -N- (imidazol id in -2 -on -1 -yl) - 2-iminoacetamido_7-3-pyridino metyl - 3-cephem-4-karbonat (syn-form). 7-[(2-aminothiazol-4-yl)-N-(imidazolidin-2-on-1-yl)-2-iminoacetamido_7-3-pyridino methyl-3-cephem-4-carbonate (syn-form) .

1,68 g 7-amino-3-(1-pyridinium)-metyl-3-cephem-4-karbonat, 20 ml tetrahydrofuran, 6,15 ml bis-trimetyl-silyl-acetamid, 0,43 ml trifluoreddiksyre og 20 ml acetonitril haes sammen ved 20°C i denne rekkefølge under omrøring. Den klare oppløsning omrører man ennå i 10 minutter, avkjøler deretter til -50°C, og tilsetter 1,8 g av det i eksmepel 2a omtalte syreklorid-hydroklorid. Deretter fjernes kuldebadet- 1.68 g 7-amino-3-(1-pyridinium)-methyl-3-cephem-4-carbonate, 20 ml tetrahydrofuran, 6.15 ml bis-trimethyl-silyl-acetamide, 0.43 ml trifluoroacetic acid and 20 ml acetonitrile is added at 20°C in this order with stirring. The clear solution is stirred for a further 10 minutes, then cooled to -50°C, and 1.8 g of the acid chloride hydrochloride mentioned in example 2a is added. The cold bath is then removed-

Etter 25 minutter er temperaturen øket til 8°C, og det har dannet seg klar oppløsning. Denn heller man i 200 ml eter, After 25 minutes, the temperature has been increased to 8°C, and a clear solution has formed. This is poured into 200 ml of ether,

og omrører i 20 minutter i i åpent kar. Den dannede utfelling frasuges, vaskes godt med eter, og oppløses i 20 ml isvann under tilsetning av 1n natronlut ved pH 7. En liten mengde (0,1 g) av en forurensning frasuges, og filtratet blandes etter hvert med til sammen 600 ml EtOH. Etter henstand natten over, frasuges, vaskes med EtOH, og tørkes. and stir for 20 minutes in an open vessel. The formed precipitate is suctioned off, washed well with ether, and dissolved in 20 ml of ice water with the addition of 1N caustic soda at pH 7. A small amount (0.1 g) of an impurity is suctioned off, and the filtrate is gradually mixed with a total of 600 ml of EtOH . After standing overnight, aspirate, wash with EtOH, and dry.

Utbytte: 1,2 g.Yield: 1.2 g.

NMR (250 MHz, 6, i d-6-DMS0): 6,70 (s, 1H, tiazolin-5). 9.5 (d, 2H, pyridinium), 8,6 (m, 1H, pyridinium), 8,2 (m, 2H, pyridinium). NMR (250 MHz, 6, in d-6-DMSO): 6.70 (s, 1H, thiazolin-5). 9.5 (d, 2H, pyridinium), 8.6 (m, 1H, pyridinium), 8.2 (m, 2H, pyridinium).

Eksempel 13aExample 13a

2-(2-imino-4-tiazolin -4- -yl )-N-(perhydro-1, 3 - diazin -2-on -1 -yl)-2-iminoeddiksyre (syn -form). 2 g 1-amino-perhydro -1,3-diazin-2-on oppløses i 30 ml vann. Etter tilsetning av 3 g 2 - (2-imino-4-tiazolin-4-yl)-glyoksylsyre omrøres 5 timer ved 20°C. Den gule utfelling frasuges, vaskes med vann, og tørkes i exikator over F^ O^. 2-(2-imino-4-thiazolin-4-yl)-N-(perhydro-1,3-diazin-2-on-1-yl)-2-iminoacetic acid (syn -form). Dissolve 2 g of 1-amino-perhydro-1,3-diazin-2-one in 30 ml of water. After adding 3 g of 2-(2-imino-4-thiazolin-4-yl)-glyoxylic acid, the mixture is stirred for 5 hours at 20°C. The yellow precipitate is filtered off, washed with water, and dried in a desiccator over F^O^.

Utbytte: 4,3 gYield: 4.3 g

Sm.p. => 260°C.Sm.p. => 260°C.

IR (nujol, karbonylområde): 1640, 1600, 1490 cm"<1.>Vanninnhold (n.f.) = 11,3$. IR (nujol, carbonyl region): 1640, 1600, 1490 cm" <1.> Water content (n.f.) = 11.3$.

NMR (250 MHz, 6, i NaOD(D20): 7,13 (s, 1H, tiazolin-5), 3,72 (t, 2H, N-N-CHg), 3,32 (t, 2H, NH-CHg), 2,9-1,99 (m, 2H, perhydrodiazin-5-H). NMR (250 MHz, 6, in NaOD(D2O): 7.13 (s, 1H, thiazolin-5), 3.72 (t, 2H, N-N-CHg), 3.32 (t, 2H, NH-CHg ), 2.9-1.99 (m, 2H, perhydrodiazine-5-H).

Aminoperhydrodiazinon ble dannet fra perhydro-1,3 - diazin-2-on ved nitrosering (NaNOg, HgSO^) og reduksjon med sinkstøv (sm.p. = 114 - 117°C). Aminoperhydrodiazinone was formed from perhydro-1,3-diazin-2-one by nitrosation (NaNOg, HgSO^) and reduction with zinc dust (m.p. = 114 - 117°C).

Eksempel 13bExample 13b

2-(2-imino-4-tiazolin-4 -yl ) -N - (perhydro -1, 3-diazin -2 -on -1 -yl)-2-iminoeddiksyreklorid-hydroklorid. 2-(2-Imino-4-thiazolin-4-yl)-N-(perhydro-1,3-diazin-2-one-1-yl)-2-iminoacetic acid chloride hydrochloride.

0,5 g av stoffet ifølge eksempel 13a (vanninnhold n. f. = 2,4.50 suspenderes i 15 ml acetonitril. Etter tilsetning av 1,63 ml SOClg omrøres 3 1/4 time ved 20°C. 0.5 g of the substance according to example 13a (water content n. f. = 2.4.50) is suspended in 15 ml of acetonitrile. After the addition of 1.63 ml of SOCl, the mixture is stirred for 3 1/4 hours at 20°C.

Den dannede utfelling frasuges deretter, vaskes med aceton-nitril, og ørkes over Pg^5i exikator. The formed precipitate is then suctioned off, washed with acetone-nitrile, and dried over a Pg 51 desiccator.

Utbytte: 0, 55 gYield: 0.55 g

IR (nujol, karbonylområdet): 1800, 1665, 1625, 1560, 1505 cm"<1>. IR (nujol, carbonyl region): 1800, 1665, 1625, 1560, 1505 cm"<1>.

Eksempel 13c Example 13c

1~[( 2 -aminotiazol -4-yl) -N- (perhydro -1, 3-diazin-2-on-1 -yl) -2 - iminoacetamido_/-3-acetoksy metyl -3-cephem-4-karbon - surt-natrium (syn-form). 1~[(2-aminothiazol-4-yl)-N-(perhydro-1,3-diazin-2-on-1-yl)-2-iminoacetamido_/-3-acetoxy methyl-3-cephem-4-carbon - acid-sodium (syn-form).

Blandingen av 5 g 7-aminocephalosporansyre, 30The mixture of 5 g of 7-aminocephalosporanic acid, 30

ml tetrahydrofuran og 9.8 bis-trimetylsilylacetamid omrøres til en dannelse av en oppløsning av 20°C (5 minutter), av-kjøles deretter til -50°C, og tilsettes 5,3 g av det ifølge eksempel 13b fremstilte syreklorid-hydroklorid. Deretter fjernes kuldebadet. Etter 40 minutter (indre temperatur da 18°C) helles reaksjonsblandingen i 500 ml eter. Man omrører 1 åpent kar 20 minutter, frasuger, vasker med eter, og opp-løser utfellingen i 50 ml isvann, idet man innstiller slutt-pH ved hjelp av 2n natronlut, på 7,5. Man frasuger meget lite uoppløst, og tilsetter til filtratet (75 ml) 500 ml ml of tetrahydrofuran and 9.8 bis-trimethylsilylacetamide are stirred to form a solution of 20°C (5 minutes), then cooled to -50°C, and 5.3 g of the acid chloride hydrochloride prepared according to example 13b are added. The cold bath is then removed. After 40 minutes (internal temperature then 18°C), the reaction mixture is poured into 500 ml of ether. One stirs 1 open vessel for 20 minutes, aspirates, washes with ether, and dissolves the precipitate in 50 ml of ice water, adjusting the final pH to 7.5 using 2N caustic soda. Very little undissolved is sucked off, and 500 ml is added to the filtrate (75 ml).

EtOH, og deretter 500 ml isopropanol. Man omrører ennå iEtOH, and then 500 ml of isopropanol. You still stir in

20 minutter,frasuger og vasker godt med isopropanol.20 minutes, vacuum and wash well with isopropanol.

Utbytte: 3.5 g.Yield: 3.5 g.

NMR: 250 MHz, 6, i CD^OD): 7,17 (s, 1H. tiazolin-5), 5,87 (d, 1H, J = 5 Hz, B-lactam). 5,2 (d, 1H, J = 5Hz, NMR: 250 MHz, 6, in CD₂OD): 7.17 (s, 1H, thiazoline-5), 5.87 (d, 1H, J = 5 Hz, β-lactam). 5.2 (d, 1H, J = 5Hz,

B-lactam), CHg-OAc blandt utveksl bare), 3,76-3,6 (m, 3H, N-N- ■' CH2og C-2), 3,45-3,28 (m, 3H, NH-CH2og C-2), 2,11 (ps.s.5H, perhydrodiazin-5-H- og 0-CO-CH^). B-lactam), CHg-OAc among exchanges only), 3.76-3.6 (m, 3H, N-N- ■' CH2 and C-2), 3.45-3.28 (m, 3H, NH-CH2 and C-2), 2.11 (ps.s. 5H, perhydrodiazine-5-H- and O-CO-CH^).

i<1>i<1>

Eksempel 14Example 14

7-[( 2 -aminotiazol-4-yl)-N-(perhydro-1, 3-diazin - 2 -on -1 -yl) -2 -iminoace tamido_7 -3-aminokarbonyloksy me tyl -3-cephe.m-4-karbon surt-natrium (syn-form). 7-[(2-aminothiazol-4-yl)-N-(perhydro-1,3-diazin-2-one-1-yl)-2-iminoacetamido_7-3-aminocarbonyloxy methyl-3-cephe.m- 4-carbon acid sodium (syn form).

Blandingen av 4, 03 g 7-amino-3-aminokarbonyloksy-metyl-3-cephem-4-karbonsurt natrium, 40 ml tetrahydrof uran, 15.7 ml bis-trimetylsilylacetamid, 40 ml acetonitril og 1,1 ml trifluoreddiksyre omrøres 40 minutter ved 20°C, og det da klare oppløsning avkjøles til -50°C Deretter tilsettes 4,27 g av det ifølge eksempel 13b fremstilte syreklorid-hydroklorid, om blandingen omrøres i 10 minutter ved -50°C. The mixture of 4.03 g of 7-amino-3-aminocarbonyloxy-methyl-3-cephem-4-carboxylic acid sodium, 40 ml of tetrahydrofuran, 15.7 ml of bis-trimethylsilylacetamide, 40 ml of acetonitrile and 1.1 ml of trifluoroacetic acid is stirred for 40 minutes at 20 °C, and the then clear solution is cooled to -50°C. Then 4.27 g of the acid chloride hydrochloride prepared according to example 13b is added, if the mixture is stirred for 10 minutes at -50°C.

Man fjerner deretter kuldebadet, lar det videreomrøre ved værelse stemperatur, inntil det etter ca. 20 minutter ved en temperatur på 8°C har dannet seg en klar oppløsning. Denne helles i 600 ml eter, omrøres 20 minutter i åpent kar, den dannede utfelling frasuges, vaskes godt med eter, og innføres deretter i 50 ml isvann, og derved innstilles ved hjelp av 2n natronlut pH endelig til 7-7,5- Man frasuger en liten mengde forurensning (1,2 g) og setter deretter til filtratet etter hvert tilsammen 850 ml EtOH. Man omrører deretter ennå 1 time ved 20°C, frasuger, vaskes med EtOH og tørker med exikator over Po<0>r. The cold bath is then removed, it is allowed to continue stirring at room temperature, until after approx. 20 minutes at a temperature of 8°C, a clear solution has formed. This is poured into 600 ml of ether, stirred for 20 minutes in an open vessel, the precipitate formed is suctioned off, washed well with ether, and then introduced into 50 ml of ice water, thereby adjusting the pH finally to 7-7.5- Man aspirate a small amount of impurity (1.2 g) and then gradually add to the filtrate a total of 850 ml of EtOH. It is then stirred for a further 1 hour at 20°C, filtered off with suction, washed with EtOH and dried with a desiccator over Po<0>r.

<■ 5 <■ 5

Utbytte: 3.15 g.Yield: 3.15 g.

NMR (250 MHz, 6, i CD^OD/DgO)-: 7,6 (s, 1H, tiazolin-5), 5,84 (d, 1H, J = 5 Hz, B-lactam), 5,14 (d, 1H, J = 5 Hz, B-lactam), (CH^OCONHg bl andt utveksl bare), 3,76-3,56 (m, 3H, N-N-CH2og C-2), 3,42-3,22 (m, 3H, CHg-NH o.g C-2), 2,0 (m, NMR (250 MHz, 6, in CD^OD/DgO)-: 7.6 (s, 1H, thiazoline-5), 5.84 (d, 1H, J = 5 Hz, B-lactam), 5.14 (d, 1H, J = 5 Hz, B-lactam), (CH^OCONHg bl and exchange only), 3.76-3.56 (m, 3H, N-N-CH2and C-2), 3.42-3 .22 (m, 3H, CHg-NH and C-2), 2.0 (m,

2H, perhydrodiazin-5-C).2H, perhydrodiazine-5-C).

Eksempel 15 Example 15

7-/"(2 -aminotiazol -4-yl ) -N- (perhydro -1, 3-diazin - 2 -on -1 -yl )-2-iminoacetamido__7-3-pyridiniometyl-3-cephem-4-karbonat (syn-form). 7-/"(2-aminothiazol-4-yl)-N-(perhydro-1,3-diazin-2-one-1-yl)-2-iminoacetamido__7-3-pyridiniomethyl-3-cephem-4-carbonate ( sight form).

2,52 g 7-amino-3-(1-pyridinium)-metyl-3-cephem-4-karbonat, 30 ml tetrahydrofuran, 0,64 ml trifluoreddiksyre, 9,25 ml bis-trimetylsilylacetamid og 30 ml acetonitril haes sammen i denne rekkefølge ved 20°C, og omrøres 5 til 10 minutter. Den da klare oppløsning avkjøles til -50°C, og tilsettes 3,24 g (2,81 g renstoff) av det i eksempel 13b omtalte syreklorid-hydroklorid. Deretter fjernes kuldebadet, og omrøres 2 timer.. 2.52 g of 7-amino-3-(1-pyridinium)-methyl-3-cephem-4-carbonate, 30 ml of tetrahydrofuran, 0.64 ml of trifluoroacetic acid, 9.25 ml of bis-trimethylsilylacetamide and 30 ml of acetonitrile are combined in this order at 20°C, and stirred for 5 to 10 minutes. The then clear solution is cooled to -50°C, and 3.24 g (2.81 g pure substance) of the acid chloride hydrochloride mentioned in example 13b are added. The cold bath is then removed, and stirred for 2 hours.

ved værelse stemperatur. Den dannede utfelling suges fra, vaskes med tetrahydrofuran/acetonitril (1:1) og med eter og tørke s. at room temperature. The formed precipitate is suctioned off, washed with tetrahydrofuran/acetonitrile (1:1) and with ether and dried.

Utbytte: 2, 7 g.- (A)Yield: 2.7 g.- (A)

Råmoderluten helles i 600 ml eter, den dannede utfelling frasuges, oppløses i 25 ml isvann ved hjelp av The crude mother liquor is poured into 600 ml of ether, the precipitate formed is suctioned off, dissolved in 25 ml of ice water using

. 300 ml EtOH utfelles en annen fraksjon.. 300 ml of EtOH precipitate another fraction.

Utbytte: 1,5 g (B).Yield: 1.5 g (B).

NMR (Substans A) (250 MHz, 6, i CD 0D/D20 ref. til MeOH): 9,13 (d, 2H) og 8,63 (t, 1H) og 8,15 (m, 3H) pyridinium, 7,06 (s, 1H, tiazolin-5), 5,92 (d, 1H, J = 5Hz, B-lactam), 5, 73 og 5,35 (AB, 2H, Cu2-pyr idin ium), 5,26 (d, 1H, J = 5Hz, B-lactam), 2,07 (m, 2H, perhydrodiazin-5-C). NMR (Substance A) (250 MHz, 6, in CD OD/D 2 O ref. to MeOH): 9.13 (d, 2H) and 8.63 (t, 1H) and 8.15 (m, 3H) pyridinium, 7.06 (s, 1H, thiazolin-5), 5.92 (d, 1H, J = 5Hz, B-lactam), 5.73 and 5.35 (AB, 2H, Cu2-pyridinium), 5 .26 (d, 1H, J = 5Hz, B-lactam), 2.07 (m, 2H, perhydrodiazine-5-C).

Eksempel 16Example 16

I- L (2-aminotiazol-4-yl)-N-(perhydro-1,3-diazin-2- on-1-yl)-2-iminoacetamido7-3-/l1-me tylte trazol-5-yl)-tiometyl7-3-cephem-4--karbonsurt natrium (syn-form). 1- L (2-Aminothiazol-4-yl)-N-(perhydro-1,3-diazin-2-on-1-yl)-2-iminoacetamido7-3-(11-methyltrazol-5-yl) -thiomethyl7-3-cephem-4-carbonic acid sodium (syn form).

1,75 g 7-amino-3-Z (1-me tyltetrazol-5-yl)-tiome tyl_7~ 3- cephem-4-karboksylsyre, 20 ml te trahydrof ur an, 5,65 ml bis-trimetylsilylacetamid og 20 ml acetonitril omrøres 20 minutter ved 20°C. Den da klare oppløsning avkjøles til -50°C. 2 g 1.75 g of 7-amino-3-Z (1-methyltetrazol-5-yl)-thiomethyl_7~ 3-cephem-4-carboxylic acid, 20 ml of tetrahydrofuran, 5.65 ml of bis-trimethylsilylacetamide and 20 ml acetonitrile is stirred for 20 minutes at 20°C. The then clear solution is cooled to -50°C. 2 g

( = 1,73 g rent stoff) av det i eksempel 13 b omtalte syreklorid-hydroklor id tilsettes,kuldebadet fjernes, og blandingen omrøres ca. 25 minutter ved omgivelsestemperatur. Den deretter klare oppløsning har da +10°C, og helles i 400 ml eter. Man omrører i åpent kar i 20 minutter, frasuger utfellingen, og oppløser den i 20 ml isvann under tilsetning av 2n natronlut ved pH 7 - 7,5. En liten mengde av en forurensning frasuges, og filtratet blandes med 700 ml EtOH, deretter med 500 ml eter. Den dannede utfelling frasuges, vaskes med eter og tørkes. (= 1.73 g pure substance) of the acid chloride-hydrochloride mentioned in example 13 b is added, the cold bath is removed, and the mixture is stirred approx. 25 minutes at ambient temperature. The then clear solution is then at +10°C, and is poured into 400 ml of ether. Stir in an open vessel for 20 minutes, suck off the precipitate, and dissolve it in 20 ml of ice water while adding 2N caustic soda at pH 7 - 7.5. A small amount of an impurity is aspirated, and the filtrate is mixed with 700 ml of EtOH, then with 500 ml of ether. The formed precipitate is filtered off, washed with ether and dried.

Utbytte: 0,9 gYield: 0.9 g

NMR: (250 MHz,6, i CD^D/DgO, ref. til MeOH = 3,3 ppm): 7,05 (s, 1H, tiazolin-5), 5,83 (d, 1H, J = 5Hz, B-lactam), 5,13 (d, 1H, J = 5Hz, g-lactam), 4,38 og 4,28 NMR: (250 MHz,6, in CD^D/DgO, ref. to MeOH = 3.3 ppm): 7.05 (s, 1H, thiazolin-5), 5.83 (d, 1H, J = 5Hz , β-lactam), 5.13 (d, 1H, J = 5Hz, β-lactam), 4.38 and 4.28

(AB, 2H, CH2-S-tetrazol), 4, 0 (s, 3H, Me-tetrazol ), 3.84-3.69 (m, 3H, N-N-CH2og C-2, AB del), 3,52 (AB del v C-2, 1H), 3,3 (ps.s. 2H, CH2-NH), 2,06 (tn, 2H, perhydrodiazin-C-5)• (AB, 2H, CH2-S-tetrazole), 4.0 (s, 3H, Me-tetrazole), 3.84-3.69 (m, 3H, N-N-CH2and C-2, AB part), 3.52 (AB part v C-2, 1H), 3.3 (ps.s. 2H, CH2-NH), 2.06 (tn, 2H, perhydrodiazine-C-5)•

Claims (2)

1. Syrehalogenider, karakterisert ved at de har den generelle formel IV 1. Acid halides, characterized in that they have the general formula IV hvori; n betyr 2, 3 eller H, og X betyr et halogenatom.in which; n means 2, 3 or H, and X means a halogen atom. 2. Fremgangsmåte til fremstilling av syrehalogenid med den generelle formel IV, karakterisert ved at aminotiazolylglykolsyre 2. Process for the production of acid halide with the general formula IV, characterized in that aminothiazolylglycolic acid omsettes med hydrazonforbindelsen hvori n har den i krav I angitte betydning til syren V hvori n har ovennevnte betydning, og denne omsttes med et halogeneringsmiddel.is reacted with the hydrazone compound in which n has the meaning specified in claim I to the acid V in which n has the above-mentioned meaning, and this is reacted with a halogenating agent. '3. Fremgangsmåte ifølge krav 1, karakterisert ved at omsetningen av syren V med halogenerings-midlet gjennomføres med et tionylklorid som halogeneringsmiddel i acetonitril eller et lavere nitroalifat, idet tionylklorid anvendes i overskudd over syrer V, og idet videre reaksjonsblandingen før tilsetningen av tionylklorid bringes til et. vanninnhold som tilsvarer et molforhold syre V/H2 0 fra 1:2 til 1 :iJ.'3. Process according to claim 1, characterized in that the reaction of the acid V with the halogenating agent is carried out with a thionyl chloride as halogenating agent in acetonitrile or a lower nitroaliphate, thionyl chloride being used in excess over acids V, and further bringing the reaction mixture before the addition of thionyl chloride to a water content corresponding to a molar ratio acid V/H2 0 from 1:2 to 1 :iJ.
NO814079A 1980-06-06 1981-11-30 ACID HALOGENIDES AND PROCEDURES FOR THEIR PREPARATION NO814079L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803021373 DE3021373A1 (en) 1980-06-06 1980-06-06 METHOD FOR PRODUCING 2- (2-AMINOTHIAZOL-4-YL) -N- (IMIDAZOLIDIN-2-ON-1-YL) 2-IMINOACETYLCEPHALOSPORINES OF THE SYN FORM

Publications (1)

Publication Number Publication Date
NO814079L true NO814079L (en) 1981-12-07

Family

ID=6104048

Family Applications (2)

Application Number Title Priority Date Filing Date
NO811756A NO811756L (en) 1980-06-06 1981-05-22 2- (2-AMINOTIAZOL-4-YL) -N- (IMIDAZOLIDIN-2-ON-1-YL) -2-IMINOACETYLCEPHALOSPORINES OF SYN-FORM, AND PROCEDURES FOR THEIR PREPARATION
NO814079A NO814079L (en) 1980-06-06 1981-11-30 ACID HALOGENIDES AND PROCEDURES FOR THEIR PREPARATION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO811756A NO811756L (en) 1980-06-06 1981-05-22 2- (2-AMINOTIAZOL-4-YL) -N- (IMIDAZOLIDIN-2-ON-1-YL) -2-IMINOACETYLCEPHALOSPORINES OF SYN-FORM, AND PROCEDURES FOR THEIR PREPARATION

Country Status (13)

Country Link
EP (1) EP0041655B1 (en)
JP (1) JPS5726693A (en)
AR (1) AR228357A1 (en)
AU (1) AU7133381A (en)
CA (1) CA1161429A (en)
DE (2) DE3021373A1 (en)
DK (1) DK248781A (en)
ES (1) ES502811A0 (en)
FI (1) FI811739L (en)
IL (1) IL63031A0 (en)
NO (2) NO811756L (en)
PT (1) PT73092B (en)
ZA (1) ZA813772B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3809561A1 (en) * 1988-03-22 1989-10-05 Hoechst Ag ESTER OF 7- (2- (2-AMINOTHIAZOL-4-YL) -2- (Z) - HYDROXYIMINOACETAMIDO) -3-METHOXYMETHYL-3-CEPHEM-4-CARBONIC ACID, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL ACCESSORIES CONTAINING IT
US8314247B2 (en) 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2818263A1 (en) * 1978-04-26 1979-11-08 Bayer Ag BETA LACTAMANTIBIOTICS

Also Published As

Publication number Publication date
EP0041655A3 (en) 1982-02-24
ES8203909A1 (en) 1982-04-01
DK248781A (en) 1981-12-07
ES502811A0 (en) 1982-04-01
CA1161429A (en) 1984-01-31
FI811739L (en) 1981-12-07
EP0041655A2 (en) 1981-12-16
ZA813772B (en) 1982-06-30
IL63031A0 (en) 1981-09-13
DE3165040D1 (en) 1984-08-30
PT73092A (en) 1981-06-01
AR228357A1 (en) 1983-02-28
NO811756L (en) 1981-12-07
PT73092B (en) 1982-07-05
AU7133381A (en) 1981-12-10
EP0041655B1 (en) 1984-07-25
JPS5726693A (en) 1982-02-12
DE3021373A1 (en) 1981-12-17

Similar Documents

Publication Publication Date Title
EP0244637B1 (en) Starting compounds for 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for their preparation
KR20010005907A (en) Crystalline amine salt of cefdinir
EP0286145A2 (en) 3-Heterocyclylthiomethyl cephalosporins
US20040242556A1 (en) Novel crystalline form of cefdinir
JPS63152370A (en) Novel carboxylic acid
PL122458B1 (en) Process for preparing novel acyl derivatives
IL118221A (en) Substituted cephalosporins, process for their preparation and pharmaceutical compositions containing them
CA1340604C (en) Process for the preparation of 7-[2-(2-aminothiazol-4-y1)-2-hydroxyiminoacetamido]-3-cephem compounds
US20050020561A1 (en) Process for the preparation of cefpodoxime acid
US5589594A (en) Process for the preparation of cephem prodrug esters
EP0272487A1 (en) Cephalosporin derivatives and their crystalline derivatives, process for the preparation of the same, intermediates for use in the synthesis of the same, pharmaceutical compositions comprising the same, and the use of the same for the manufacture of a medicament having valuable therapeutic and preventative properties
NO814079L (en) ACID HALOGENIDES AND PROCEDURES FOR THEIR PREPARATION
JPH069647A (en) New cephalosporin intermediate
WO1996026943A1 (en) Derivatives of 3-pyrrolidylidene-2-one-cephalosporines
JPS60222489A (en) Manufacture of 7-aminocephem compound
EP0204781B1 (en) Process for the production of bissilylated 3-iodomethylcephalosporine derivatives
US4237280A (en) Intermediate for cephalosporin type compound
US5831085A (en) Process for manufacture of cephalosporin such as ceftazidime and intermediate thereof
DD268947A5 (en) METHOD FOR PRODUCING STABLE, CRYSTALLINE CEPHALOSPORIN INTERCONNECTIONS
US4436904A (en) Cephalosporins
JPH01258683A (en) Production of 7-1d(-1) alpha-amino-alpha-(p- hydroxyphenyl)acetamide/-3-(1, 2, 3-triazol-4 (5)-thiomethyl-3-cephem-4-carboxylic acid 1, 2-propylene glycol and novel intermediate
US4626533A (en) 7-(2-thienylacetamido)-3-acylaminomethyl-cephalosporins
CA1197838A (en) Cephalosporins and processes for preparation thereof
EP0003329A1 (en) Cephalexin-amide complex, process for its production and use in cephalexin-monohydrate production
JPH07501311A (en) Novel 3-fused pyridinium methylcephalosporin compounds